Principal Scientist / Senior Scientist, Cancer Immunotherapy (Hematological Malignancy)

Location
San Diego, CA, United States
Posted
Mar 13, 2021
Ref
478JG
Hotbed
Biotech Beach
Required Education
Bachelors Degree
Position Type
Full time
Fate Therapeutics is seeking a dedicated individual with a background in hematological cancer immunotherapy to join a multidisciplinary team developing novel cellular therapeutics. As a key member of our cancer immunotherapy team, this position will assist in the design of targeted iPSC-derived NK and T cell therapies, provide leadership and subject matter expertise for the development of allogeneic cell therapies targeting hematopoietic malignancies, and guide the evaluation of candidate cellular therapies from proof of concept through first in human clinical trials. The successful candidate will be able to provide technical and scientific guidance within the cancer immunotherapy team and across other departments at Fate. This position will have a thorough understanding of hematological cancers and anti-tumor immunology, of scientific evaluation of cell therapy products, and an ability to connect basic research to product development. Proficiency with mammalian cell culture, immunological-based approaches and techniques (both in-vitro and in-vivo), and familiarity with current molecular biology, gene-editing, and protein engineering of lymphocytes are required. This position will join a dynamic and growing team, working closely in collaboration with, and reporting to, an Associate Director in Cancer Immunotherapy. This position is located at the Company's corporate headquarters in San Diego, California.

Responsibilities
• Lead and coordination of pre-clinical projects involving design, execution, and evaluation of
iPSC-derived NK and T cell therapy candidates.
• Serve as subject matter expert on allogeneic cell therapies for hematopoietic cancer
targeting.
• Mentor and lead junior scientists to foster a collaborative and rigorous scientific team.
• Partner with internal departments at Fate and external research partners to advance design
and development of product candidates.
• Communicate results and engage in enthusiastic discussion with immunology groups, larger
program-specific teams, and research partners.
• Presentation of findings at major international meetings and in publications.

Qualifications
• PhD degree in Immunology, Cell Biology or related fields with a minimum of 5 years of postdoctoral experience. Experience in a mid-stage biotech or pharmaceutical setting is preferred.
• In-depth experience in developing and executing assays for human NK and T cells.
• Experience with current molecular biology techniques for editing and engineering of T cells and NK cells is a plus.
• In-depth experience with current techniques for cell based analysis including multi-parameter flow cytometry, IncuCyte and/or xCELLigence, and cytokine detection (eg MSD, Isoplexis).
• In-depth experience in design and evaluation of animal studies.
• Familiarity with single cell analysis and or experience of bioinformatics.
• Excellent communication and organization skills are essential.
• Proven people management skills.
• Positive outlook and a team-oriented attitude.

Working Conditions and Physical Requirements
• Will require working with cells and cell lines of human and/or animal origin
• Will require working with hazardous materials
• 100% on-site work at corporate headquarters in San Diego, CA
• Evening and weekend work as necessary
The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time. For consideration send cover letter and resume to: careers@fatetherapeutics.com and reference job code 478JG.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). The Company's pipeline also includes ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease in patients with hematologic malignancies undergoing allogeneic stem cell transplant. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.